- Home
- VTYX vs APLT Comparison
VTYX vs APLT Comparison
Compare VTYX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- APLT
- Stock Information
- Founded
- VTYX 2018
- APLT 2016
- Country
- VTYX United States
- APLT United States
- Employees
- VTYX N/A
- APLT N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- VTYX Health Care
- APLT Health Care
- Exchange
- VTYX Nasdaq
- APLT Nasdaq
- Market Cap
- VTYX 154.9M
- APLT 178.6M
- IPO Year
- VTYX 2021
- APLT 2019
- Fundamental
- Price
- VTYX $10.38
- APLT $0.25
- Analyst Decision
- VTYX Strong Buy
- APLT Buy
- Analyst Count
- VTYX 5
- APLT 5
- Target Price
- VTYX $14.60
- APLT $4.13
- AVG Volume (30 Days)
- VTYX 2.5M
- APLT 25.0M
- Earning Date
- VTYX 11-06-2025
- APLT 11-13-2025
- Dividend Yield
- VTYX N/A
- APLT N/A
- EPS Growth
- VTYX N/A
- APLT N/A
- EPS
- VTYX N/A
- APLT N/A
- Revenue
- VTYX N/A
- APLT $1,000,000.00
- Revenue This Year
- VTYX N/A
- APLT N/A
- Revenue Next Year
- VTYX N/A
- APLT $5,935.35
- P/E Ratio
- VTYX N/A
- APLT N/A
- Revenue Growth
- VTYX N/A
- APLT N/A
- 52 Week Low
- VTYX $0.78
- APLT $0.22
- 52 Week High
- VTYX $10.47
- APLT $10.48
- Technical
- Relative Strength Index (RSI)
- VTYX 74.09
- APLT 27.49
- Support Level
- VTYX $8.90
- APLT $0.25
- Resistance Level
- VTYX $10.02
- APLT $0.40
- Average True Range (ATR)
- VTYX 0.78
- APLT 0.11
- MACD
- VTYX -0.10
- APLT -0.05
- Stochastic Oscillator
- VTYX 94.86
- APLT 4.17
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.